Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes

Laparoscopic parenchyma-sparing liver resection for colorectal metastases

“…Nevertheless, over the years, PSLR has increasingly been used for CLM. 6,33 There are two main reasons for this: the evolution of the concept of resectability and the increased knowledge on tumor biology. 34,35 Over the past decades, the concept of tumor resectability in CLM has changed significantly.…”

“…[37][38][39][40][41][42] PSLR is an essential part of multimodal treatment of CLM, as it avoids unnecessary removal of normal parenchyma and is associated with less surgical stress, fewer postoperative complications and feasibility of future resections. 6,33,43 LLR is becoming an important alternative to conventional open surgery. In this study we included patients who primarily underwent LPSLR for CLM.…”

Update on Surgical Management of Small Bowel Neuroendocrine Tumors

“…Denucleation or parenchymal-sparing hepatectomy is currently the most preferable approach for many surgeons (45,46). Combining surgery and RFA or MWA may be a feasible approach for preserving postoperative liver function.…”

Liver transplantation for unresectable colorectal liver metastases: A systematic review

“…Half of patients with CRC will develop liver metastases during the course of their disease resulting in two‐thirds of CRC‐related deaths . Hepatectomy is the only potentially curative treatment available for resectable colorectal liver metastases (CLM) with low operative mortality (1‐2%) and a 5‐year survival of up to 50‐60% . Disease recurrence occurs, however, in 70% of patients most often during the first 3 years after surgery .…”